Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.52 |
| ▸ | PIM1 | P11309 | 10/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 10/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15588810 | 0.91 | PIM2 (0.51) | PIM2PIM1PIM3MLYCDPDK2 | |
| SCHEMBL11907190 | 0.91 | PIM1 (0.45) | PIM2PIM1PIM3MLYCDXDH | |
| SCHEMBL11978319 | 0.90 | PIM2 (0.53) | PIM2PIM1PIM3MLYCDPDK2 | |
| SCHEMBL11906672 | 0.87 | PLAU (0.41) | PIM2PIM1PIM3HDAC1HDAC6 | |
| SCHEMBL2185606 | 0.85 | PIM1 (0.47) | PIM2PIM1PIM3MLYCDPDK2 | |
| SCHEMBL11906490 | 0.84 | GABRA5 (0.41) | PIM2PIM1PIM3MLYCDXDH | |
| SCHEMBL11908359 | 0.84 | PDE2A (0.40) | PIM2PIM1PIM3PDK2HDAC1 | |
| SCHEMBL11909195 | 0.83 | PIM1 (0.41) | PIM2PIM1PIM3MLYCDXDH | |
| SCHEMBL11907804 | 0.82 | ALDH1A1 (0.42) | PIM2PIM1PIM3PDK2MAPK14 | |
| SCHEMBL11907368 | 0.82 | ATR (0.50) | PIM2PIM1PIM3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173883-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8987457-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| US-8987457-B2 | Ring-substituted N-pyridinyl amides as kinase inhibitors | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| WO-2014033631-A1 | N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133473-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM2 2/4885PIM1 1/4885PIM3 4/4885 |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | PIM2 4/4885PIM1 1/4885PIM3 5/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM2 2/4885PIM1 1/4885PIM3 4/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.